Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Findings give hope to plant extract as possible lupus treatment

25.09.2014

New findings by a biomedical engineer and his team at the University of Houston (UH) raise hope for a new class of drugs to treat lupus that may not include the long list of adverse risks and side effects often associated with current treatments for this disease.

Lupus, or systemic lupus erythematosus, is a progressive, degenerative disease in which the immune system turns against itself, attacking a person's healthy tissue, cells and organs. Symptoms range from debilitating pain and fatigue to organ failure and a host of other impairments. An estimated 1.5 million Americans, and at least five million people worldwide, have a form of lupus.


New findings by UH biomedical engineer Chandra Mohan and his team raise hope for a new class of drugs to treat lupus that may not include the long list of adverse risks and side effects often associated with current treatments.

Credit: Cullen College of Engineering Office of Communications

Though there is no cure, a UH researcher and his team are actively working toward finding new treatments and, ultimately, a cure. Chandra Mohan, Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering in the UH Cullen College of Engineering, and his group's latest work could lead to new, more natural therapeutics for lupus that use a plant-derived chemical. The promising findings were recently published in Arthritis & Rheumatology, the monthly journal of the American College of Rheumatology.

With only one drug specifically approved for the treatment of lupus in the past 50 years, lupus patients are commonly treated with steroids, a class of immunosuppressive drugs that delay the development and progression of the disease by suppressing the immune system. By suppressing the immune system in its entirety, however, this mode of treatment carries with it an increased risk of infections and other harmful side effects.

In this latest research, Mohan and his colleagues present new findings that detail the use of a synthetic, plant-derived compound – abbreviated CDDO – that was shown to effectively suppress the multiple steps of lupus development in murine models, including the onset of kidney disease.

One of the most common organs to be attacked by lupus is the kidney, manifesting in lupus nephritis. While this condition doesn't affect all lupus sufferers, an estimated 40 percent of lupus patients develop it. Lupus nephritis, which causes inflammation of the kidneys and impairs their ability to effectively rid the body of waste products and other toxins, is the leading cause of lupus-related deaths and results in tens of thousands of hospitalizations per year.

"The development of lupus is a two-step reaction. First, the immune system develops antibodies that attack the body's own DNA, then that activated immune system attacks the kidneys," Mohan said. "We found that CDDO may block both of these steps."

Mohan says there is much left to be discovered about CDDO, including how it works in suppressing the progression of lupus. The next step for this research is to confirm whether the CDDO compound suppresses the immune system across the board, or whether it simply suppresses the activation of the specific signaling pathways that lead to the development of lupus. To find this out, Mohan's group will test it in the lab to see if they can mount the proper immune response. If not, Mohan says the compound likely could be suppressing the entire immune system, which is the current problem with using steroids to treat lupus. Even if the compound is shown to be generally immunosuppressive, however, it still may be a better treatment option than steroids for some patients.

"The most exciting part of this research is that CDDO is originally plant-derived, so it's relatively natural and carries less chance of side effects," Mohan said. "That's a very important point, because many of the current therapeutic agents being used for lupus have significant side effects. As far as we have tested in these experiments, we found that the CDDO compound had no known side effects. Additionally, compared to many other test compounds we've previously tried for treating lupus, this one appears to be much more effective."

While it will take time to validate this before the compound can move from testing in the lab to clinical trials in humans, Mohan is encouraged by the prospect of treating lupus patients with more natural compounds that have fewer side effects.

###

About the University of Houston

The University of Houston is a Carnegie-designated Tier One public research university recognized by The Princeton Review as one of the nation's best colleges for undergraduate education. UH serves the globally competitive Houston and Gulf Coast Region by providing world-class faculty, experiential learning and strategic industry partnerships. Located in the nation's fourth-largest city, UH serves more than 40,900 students in the most ethnically and culturally diverse region in the country. For more information about UH, visit the university's newsroom at http://www.uh.edu/news-events/.

About the Cullen College of Engineering

The UH Cullen College of Engineering, established in 1941, is accredited by the Engineering Accreditation Commission of ABET. More than 4,600 students are enrolled in engineering courses – 3,536 undergraduates, as well as 817 master's and doctoral students in biomedical, chemical, civil, computer, electrical, environmental, geosensing systems, industrial, mechanical and petroleum engineering. The college also offers interdisciplinary graduate programs in subsea, aerospace, materials, and computer and systems engineering. Chemical and mechanical engineering have ranked among the top programs nationally.

To receive UH science news via email, sign up for UH-SciNews at http://www.uh.edu/news-events/mailing-lists/sciencelistserv/index.php.

For additional news alerts about UH, follow us on Facebook at http://www.facebook.com/UHNewsEvents and Twitter at http://twitter.com/UH_News

Lisa Merkl | Eurek Alert!

Further reports about: Mohan compounds extract findings immune immune system lupus treatment nephritis steps steroids treating

More articles from Life Sciences:

nachricht Newly designed molecule binds nitrogen
23.02.2018 | Julius-Maximilians-Universität Würzburg

nachricht Atomic Design by Water
23.02.2018 | Max-Planck-Institut für Eisenforschung GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Attoseconds break into atomic interior

A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.

In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...

Im Focus: Good vibrations feel the force

A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.

By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Basque researchers turn light upside down

23.02.2018 | Physics and Astronomy

Finnish research group discovers a new immune system regulator

23.02.2018 | Health and Medicine

Attoseconds break into atomic interior

23.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>